| 2026-03-02 |
详情>>
内部人交易：
Campbell Bradley L股份减少22500.00股
|
| 2026-02-20 |
详情>>
股本变动：
变动后总股本31400.07万股
|
| 2026-02-20 |
详情>>
业绩披露：
2025年年报每股收益-0.09美元,归母净利润-2711万美元,同比去年增长51.68%
|
| 2026-02-02 |
股东大会：
将于2026-03-03召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger (which we refer to, as it may be amended from time to time, as the “Merger Agreement”), dated December 19, 2025, by and among Amicus, BioMarin Pharmaceutical Inc., a Delaware corporation (which we refer to as “BioMarin”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin (which we refer to as “Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into Amicus (which we refer to as the “Merger”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin (we refer to this proposal as the “Merger Proposal”);
2.To consider and vote on the proposal to approve, by non-binding, advisory vote, compensation that may be paid or become payable to Amicus’ named executive officers that is based on or otherwise relates to the Merger (we refer to this proposal as the “Compensation Proposal”);
3.To consider and vote on any proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the Merger Proposal at the time of the Special Meeting (we refer to this proposal as the “Adjournment Proposal”).
|
| 2025-12-19 |
复牌提示：
2025-12-19 07:40:00 停牌，复牌日期 2025-12-19 08:00:00
|
| 2025-11-04 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.09美元,归母净利润-2880万美元,同比去年增长59.35%
|
| 2025-11-04 |
财报披露：
美东时间 2025-11-04 盘前发布财报
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益-0.15美元,归母净利润-4610.6万美元,同比去年增长28.09%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-0.07美元,归母净利润-2168.6万美元,同比去年增长55.21%
|
| 2025-04-24 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.Elect four Class III directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2028 Annual Meeting or until their respective successors have been elected;
2.Approve the Amicus Therapeutics, Inc. 2025 Equity Incentive Plan;
3.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.Approve, on an advisory basis, the Company’s executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2025-02-19 |
详情>>
业绩披露：
2022年年报每股收益-0.82美元,归母净利润-2.37亿美元,同比去年增长5.55%
|
| 2025-02-19 |
详情>>
业绩披露：
2024年年报每股收益-0.18美元,归母净利润-5610.6万美元,同比去年增长62.99%
|
| 2024-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.4美元,归母净利润-1.18亿美元,同比去年增长34.84%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.23美元,归母净利润-7084.5万美元,同比去年增长39.83%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.21美元,归母净利润-6411.6万美元,同比去年增长33.33%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.16美元,归母净利润-4841.9万美元,同比去年增长8.53%
|
| 2024-04-24 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.Elect three Class II directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2027 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool;
3.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.Approve, on an advisory basis, the Company’s executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-0.51美元,归母净利润-1.52亿美元,同比去年增长35.92%
|
| 2023-04-26 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.Elect two Class I directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2026 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool;
3.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
4.Approve, on an advisory basis, the Company’s executive compensation;
5.Approve, on an advisory basis, the frequency of stockholder advisory votes on executive compensation;
6.Approve the Amicus Therapeutics, Inc. 2023 Employee Stock Purchase Plan;
7.Approve the Amendment to the Company’s Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as pursuant to 2022 amendments to the Delaware General Corporation Law;
8.Consider and act upon any other business that is properly presented at the meeting.
|
| 2022-04-26 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.Elect five Class III directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2025 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan to add 6,000,000 shares to the equity pool;
3.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.Approve, on an advisory basis, the Company’s executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2024 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool;
3.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.Approve, on an advisory basis, the Company’s executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2020-04-24 |
股东大会：
将于2020-06-04召开股东大会
会议内容 ▼▲
- 1.Elect four Class I directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2023 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan to add 9,500,000 shares to the equity pool;
3.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.Approve, on an advisory basis, the Company’s executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2019-04-29 |
股东大会：
将于2019-06-27召开股东大会
会议内容 ▼▲
- 1.Elect four Class III directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2022 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool;
3.Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.Approve, on an advisory basis, the Company's executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2018-04-27 |
股东大会：
将于2018-06-07召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2021 Annual Meeting or until their respective successors have been elected;
2.Approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that we are authorized to issue from 250,000,000 shares to 500,000,000 shares
3.Approve the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool
4.Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018;
5.Approve, on an advisory basis, the Company's executive compensation;
6.Consider and act upon any other business that is properly presented at the meeting.
|
| 2017-04-28 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.Elect two Class I directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2020 Annual Meeting or until their respective successors have been elected;
2.Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.Approve, on an advisory basis, the Company's executive compensation;
4.Approve, on an advisory basis, the frequency of the vote on executive compensation;
5.Consider and act upon any other business that is properly presented at the meeting.
|
| 2016-04-29 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1.Elect four Class III directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2019 Annual Meeting or until their respective successors have been elected;
2.Approve the Amended and Restated 2007 Equity Incentive Plan,
3.Approve the issuance of shares of the Company's common stock in connection with a specific milestone payment that may become payable to the former Scioderm stockholders, in accordance with the Marketplace Rules of the NASDAQ Stock Market, LLC;
4.Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016;
5.Approve, on an advisory basis, the Company's executive compensation;
6.Consider and act upon any other business that is properly presented at the meeting.
|